Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Inspectorate Begins Enforcing New Drug GMPs Overseas

This article was originally published in PharmAsia News

Executive Summary

Inspections are part of a bid to raise domestic quality to global standards

You may also be interested in...



What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 1 of 2)

SHANGHAI - Multinational pharma companies need to review their manufacturing practices to ensure full compliance with China's new GMP regulations, which went into effect March 1

Can We Talk? US FDA Remote Records Review Missteps Worry Industry

Alkermes CRL is just the latest fallout from black-hole process.

US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements

Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel